doi:10.3969/j.issn.1004-583X.2025.02.016

Abstract

CLC Number:

R563.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://lchc.magtechjournal.com/EN/10.3969/j.issn.1004-583X.2025.02.016

https://lchc.magtechjournal.com/EN/Y2025/V40/I2/185

References 55

[1]	Tamura A, Matsubara K, Tanaka T, et al. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children[J]. J Infect, 2008, 57(3):223-228.
[2]	中华医学会儿科学分会呼吸学组. 儿童社区获得性肺炎管理指南(2013修订)[J]. 中华儿科杂志, 2013, (10):745-752.
[3]	潘艳艳. 难治性支原体肺炎患儿血清铁蛋白水平变化及其意义[J]. 山东医药, 2015, 55(38):68-70.
[4]	Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults[J]. N Engl J Med, 2015, 373(5):415-427.
[5]	Liu WK, Liu Q, Chen DH, et al. Epidemiology of acute respiratory infections in children in Guangzhou: A three-year study[J]. PLoS One, 2014, 9(5):e96674.
[6]	崔京涛. 肺炎支原体感染者血清流行病学分析及其抗菌药物疗效评价[J]. 中华检验医学杂志, 2011, 34(9):820-823.
[7]	Harris M, Clark J, Coote N, et al. British thoracic society guidelines for the management of community acquired pneumonia in children: Update 2011[J]. Thorax, 2011, 66 Suppl 2:ii1-23.
[8]	Miyashita N, Kawai Y, Inamura N, et al. Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults[J]. J Infect Chemother, 2015, 21(3):153-160. doi: 10.1016/j.jiac.2014.10.008 pmid: 25533771
[9]	Subspecialty Group of Respiratory Diseases, The Society of Pediatrics;Chinese Medical Association The Editorial Board, Chinese Journal of Pediatrics. Guidelines for management of community acquired pneumonia in children(the revised edition of 2013) (II)[J]. Zhonghua Er Ke Za Zhi, 2013, 51(11):856-862.
[10]	Wang M, Wang Y, Yan Y, et al. Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children[J]. Int J Infect Dis, 2014, 29:18-23.
[11]	Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children[J]. Pediatr Pulmonol, 2014, 49(4):377-380.
[12]	Narita M. Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis[J]. Front Microbiol, 2016, 7:23.
[13]	Meyer Sauteur PM, Theiler M, Buettcher M, et al. Frequency and clinical presentation of mucocutaneous disease due to Mycoplasma pneumoniae infection in children with community-acquired pneumonia[J]. JAMA Dermatology, 2020, 156(2):144-150.
[14]	Kassisse E, García H, Prada L, et al. Prevalence of Mycoplasma pneumoniae infection in pediatric patients with acute asthma exacerbation.[J]. Archivos Argentinos de Pediatria, 2018, 116(3):179-185. doi: 10.5546/aap.2018.eng.179 pmid: 29756701
[15]	Guo L, Liu F, Lu MP, et al. Increased T cell activation in BALF from children with refractory Mycoplasma pneumoniae Mycoplasma pneumoniae pneumonia[J]. Pediatr Pulmonol, 2015, 50(8):814-819.
[16]	Lee YC, Chang CH, Lee WJ, et al. Altered chemokine profile in pneumonia infected children[J]. J Microbiol Immunol, 2021, 54(4):673-679.
[17]	Lee E, Lee YY. Predictive factors of the responses to treatment of Mycoplasma pneumoniae pneumonia[J]. J Clin Med, 2021, 10(6):1154.
[18]	Wang Z, Li YC, Chen L. Early identification of refractory Mycoplasma pneumoniae pneumonia in children[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2015, 17(11):1189-1192.
[19]	Liu J, Zhao F, Lu J, et al. High Mycoplasma pneumoniae loads and persistent long-term Mycoplasma pneumoniae DNA in lower airway associated with severity of pediatric Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2019, 19(1):1045.
[20]	Liu C, Wang R, Ge S, et al. Research status and challenges of Mycoplasma pneumoniae pneumonia in children: A bibliometric and visualization analysis from 2011 to 2023[J]. Medicine (Baltimore), 2024, 103(11):e37521.
[21]	Huang W, Xu X, Zhao W, et al. Refractory Mycoplasma pneumonia in children: A systematic review and meta-analysis of laboratory features and predictors[J]. J Immunol Res, 2022, 2022:9227838.
[22]	管峥, 霍洁, 袁晶, 等. 血清乳酸脱氢酶联合白细胞介素18对儿童难治性肺炎支原体肺炎的预测作用[J]. 实用医学杂志, 2020, 36(20):2848-2851.
[23]	郑雪香, 林继雷, 代继宏. 基于决策曲线和剂量反应分析评估乳酸脱氢酶对儿童难治性肺炎支原体肺炎的预测价值[J]. 中国当代儿科杂志, 2020, 22(2):112-117.
[24]	Bajantri B, Venkatram S, Diaz-Fuentes G. Mycoplasma pneumoniae: A potentially severe infection[J]. J Clin Med Res, 2018, 10(7):535-544. doi: 10.14740/jocmr3421w pmid: 29904437
[25]	Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond[J]. Clin Microbiol Rev, 2017, 30(3):747-809. doi: 10.1128/CMR.00114-16 pmid: 28539503
[26]	Yang TI, Chang TH, Lu CY, et al. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter?[J]. J Microbiol Immunol Infect, 2019, 52(2):329-335.
[27]	周忠霞, 王霆, 王辉. 乳酸脱氢酶在成人社区获得性肺炎严重程度诊断中的价值[J]. 临床肺科杂志, 2017, 22(6):1026-1029.
[28]	杜玉秀, 马香萍, 多力坤·木扎帕尔. 病毒性肺炎患儿血清糖蛋白、乳酸脱氢酶变化及意义[J]. 临床儿科杂志, 2012, 30(2):138-140.
[29]	Liu X, Zhang Q, Chen H, et al. Comparison of the clinical characteristics in parents and their children in a series of family clustered Mycoplasma pneumoniae infections[J]. BMC Pulm Med, 2024, 24(1):107. doi: 10.1186/s12890-024-02922-0 pmid: 38439032
[30]	Wang S, Jiang Z, Li X, et al. Diagnostic value of serum LDH in children with refractory Mycoplasma pneumoniae pneumoniae: A systematic review and meta-analysis[J]. Front Pediatr, 2023, 11:1094118.
[31]	Li L, Guo R, Zou Y, et al. Construction and validation of a Nomogram model to predict the severity of Mycoplasma pneumoniae pneumonia in children[J]. J Inflamm Res, 2024, 17:1183-1191. doi: 10.2147/JIR.S447569 pmid: 38410419
[32]	Chen Q, Hu T, Wu L, et al. Clinical features and biomarkers for early prediction of refractory Mycoplasma pneumoniae pneumonia in children[J]. Emerg Med Int, 2024, 2024:9328177.
[33]	邸冉, 杨毅, 沈永明. 血清乳酸脱氢酶降钙素原C反应蛋白在儿童难治性肺炎支原体肺炎早期预测中的价值[J]. 实用医技杂志, 2024, 31(2):100-103.
[34]	Zhang X, Sun R, Jia W, et al. Clinical characteristics of lung consolidation with Mycoplasma pneumoniae pneumonia and risk factors for Mycoplasma pneumoniae necrotizing pneumonia in children[J]. Infect Dis Ther, 2024, 13(2):329-343. doi: 10.1007/s40121-023-00914-x pmid: 38265626
[35]	Li G, Fan L, Wang Y, et al. High co-expression of TNF-α and CARDS toxin is a good predictor for refractory Mycoplasma pneumoniae pneumonia[J]. Mol Med, 2019, 25(1):38.
[36]	Cheng Q, Zhang H, Shang Y, et al. Clinical features and risk factors analysis of bronchitis obliterans due to refractory Mycoplasma pneumoniae pneumonia in children: A nomogram prediction model[J]. BMC Infect Dis, 2021, 21(1):1085. doi: 10.1186/s12879-021-06783-4 pmid: 34674642
[37]	Choi YJ, Jeon JH, Oh JW. Critical combination of initial markers for predicting refractory Mycoplasma pneumoniae pneumonia in children: A case control study[J]. Respir Res, 2019, 20(1):193.
[38]	Xu JJ, Shu LH. Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2018, 20(1):37-42.
[39]	张佳, 申改青, 王有峰. 血清乳酸脱氢酶、D-二聚体水平与肺炎支原体肺炎患儿病情严重程度及预后的关联性[J]. 中国实用医刊, 2023, 50(4):24-27.
[40]	He W, Yin J, Wan Y. Correlations of different serological parameters with the severity and prognosis of pneumonia in children infected with Mycoplasma pneumoniae[J]. Clin Lab, 2022, 68(12):10.
[41]	Liu TY, Lee WJ, Tsai CM, et al. Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children[J]. Pediatr Neonatol, 2018, 59(5):501-506.
[42]	Lu A, Wang C, Zhang X, et al. Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children[J]. Respir Care, 2015, 60(10):1469-1475.
[43]	Chen L, Yin J, Liu X, et al. Thromboembolic complications of Mycoplasma pneumoniae pneumonia in children[J]. Clin Respir J, 2023, 17(3):187-196.
[44]	Zhang J, Wang T, Li R, et al. Prediction of risk factors of bronchial mucus plugs in children with Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2021, 21(1):67.
[45]	Moonnumakal SP, Fan LL. Bronchiolitis obliterans in children[J]. Curr Opin Pediatr, 2008, 20(3):272-278. doi: 10.1097/MOP.0b013e3282ff62e9 pmid: 18475095
[46]	Zhou L. Clinical features of Mycoplasma pneumoniae infection in respiratory tract in children in middle south of China[J]. Eur J Inflamm, 2018, 16:205873921877224.
[47]	Chen Y, Tian WM, Chen Q, et al. Clinical features and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2018, 20(8):629-634.
[48]	Zheng HQ, Ma YC, Chen YQ, Clinical analysis and risk factors of bronchiolitis obliterans after Mycoplasma pneumoniae pneumonia[J]. Infection and Drug Resistance, 2022, 15:4101-4108.
[49]	Liu JH, Liu JR, Tang XL, et al. Predictive factors for sequelae of bronchitis obliterans in refractory Mycoplasma pneumoniae pneumonia[J]. Zhonghua Er Ke Za Zhi, 2023, 61(4):317-321.
[50]	Singhal NR, Da Cruz EM, Nicolarsen J, et al. Perioperative management of shock in two fontan patients with plastic bronchitis[J]. Semin Cardiothorac Vasc Anesth, 2013, 17(1):55-60. doi: 10.1177/1089253213475879 pmid: 23381614
[51]	Saunders K, Garrett E, Crosby A, et al. Plastic bronchitis: Autopsy findings in the sudden death of a healthy pediatric patient with sickle cell disease[J]. Pediatr Blood Cancer, 2022, 69(8):e29584.
[52]	Zhong H. Analysis of clinical characteristics and risk factors of plastic bronchitis in children with Mycoplasma pneumoniae pneumonia[J]. Frontiers in Pediatrics, 2021, 9:735093.
[53]	Choi YJ, Chung EH, Lee E, et al. Clinical characteristics of macrolide-refractory Mycoplasma pneumoniae pneumonia in Korean children: A multicenter retrospective study[J]. J Clin Med, 2022, 11(2):306.
[54]	Yang L, Zhang Y, Shen C, et al. Clinical features and risk factors of plastic bronchitis caused by Mycoplasma pneumoniae pneumonia in children[J]. BMC Pulmonary Medicine, 2023, 23(1):468. doi: 10.1186/s12890-023-02766-0 pmid: 37996853
[55]	Saraya T, Watanabe T, Tsukahara Y, et al. The correlation between chest X-ray scores and the clinical findings in children and adults with Mycoplasma pneumoniae pneumonia[J]. Intern Med, 2017, 56(21):2845-2849.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 55

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wu Wanfeng, Wang Yunyun, Yang Daokun. Comparative study on the clinical efficacy of different antiviral drugs in the treatment of COVID-19 [J]. Clinical Focus, 2025, 40(2): 147-152.
[2]	Li Dengfeng, Huang Jiahu, Li Tingjun, Lv Yong, Jin Zhenzhen, Lian Shaofeng. Construction of a prediction model for refractory mycoplasma pneumoniae pneumonia in children based on lung ultrasound score [J]. Clinical Focus, 2025, 40(2): 153-157.
[3]	Yang Xiaolin, Yang Yan. Clinical characteristics of children with Mycoplasma pneumoniae infection complicated with asthmatic bronchopneumonia [J]. Clinical Focus, 2024, 39(9): 808-811.
[4]	. [J]. Clinical Focus, 2024, 39(7): 668-672.
[5]	Yu Jingyi, Si Yuanguo, Lan Cuixia, Xing Jiaxuan. Safety and efficacy of rivaroxaban in the treatment of discharged COVID-19 patients: A meta-analysis [J]. Clinical Focus, 2024, 39(6): 485-493.
[6]	Yan Yaru, Zhao Haotian, Zhang Jiesi, Wang Xiaona, Zhao Heling. Ultrasound evaluation of speckle tracking imaging on right ventricular function and right ventricular pulmonary artery coupling in severe pneumonia underwent mechanical ventilation versus common pneumonia [J]. Clinical Focus, 2024, 39(6): 531-536.
[7]	Yun Xiaoxiao, Li Shufen, Sun Fang. Clinical features of adenovirus pneumonia in immunocompetent adults: A meta-analysis [J]. Clinical Focus, 2024, 39(4): 293-303.
[8]	Zhi Bingdi, Liu Ying, Liu Ying, Zhang Fubo, Li Junfeng. SARS-CoV-2 infection combined with Listeria meningitis: A case report and literature review [J]. Clinical Focus, 2024, 39(4): 347-351.
[9]	Zhang Xia, Tang Yan, Liu Wenli, Liu Juan. Value of lung ultrasound in the assessment of community-acquired pneumonia in infants aged 1-3 months [J]. Clinical Focus, 2024, 39(3): 234-238.
[10]	Wei Fang, Zhang Yu, Wang Qingqing, Zheng Guoqi. Clinical analysis of 11 cases of coronavirus disease-19 associated with acute pancreatitis: Case report [J]. Clinical Focus, 2024, 39(3): 239-243.
[11]	Huang Saihu, Long Zhongjie, Wu Shuiyan, Bai Zhenjiang. Clinical characteristics and etiological analysis of severe pneumonia complicated with acute respiratory failure in children before and after COVID-19 [J]. Clinical Focus, 2024, 39(2): 140-143.
[12]	Yu Zeyu, Lin Xi, Chen Zhanghua, Yang Wei, Chen Zhimin, Zhang Hai. Analysis of risk factors for refractory Mycoplasma pneumoniae pneumonia in children [J]. Clinical Focus, 2024, 39(1): 43-46.
[13]	Wei Zeng, Cao Ling, She Dunmin, Liu Yan, Wang Yan, Zhang Zhenwen. The causes of death in 54 patients with type 2 diabetes mellitus complicated with COVID-19 [J]. Clinical Focus, 2023, 38(9): 806-812.
[14]	Huang Huayan, Lin Chunguang, Wu Changru, Chen Yongdong, Huang Huanmou. Clinical characteristics of patients infected with Omicron and Delta variants in novel coronavirus [J]. Clinical Focus, 2023, 38(7): 600-605.
[15]	. [J]. Clinical Focus, 2023, 38(7): 638-646.